Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mircera for renal anemia in non-dialysis CKD patients
NCT00081471Phase 3Completed
- Sponsor
- Roche
- Start
- Jun 2004
- Primary completion
- Jul 2006
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial of methoxy polyethylene glycol-epoetin beta in anemia of chronic kidney disease (2 arms), sponsored by Roche. Primary endpoint: Hemoglobin response rate at 28 weeks. Started Jun 2004; status: completed.
02
Drugs
methoxy polyethylene glycol-epoetin beta
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT00081471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081471.